The group is expanding its mRNA-4359 trial to include first-line melanoma.
ApexOnco Front Page
Recent articles
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
